In recent years, the literature has turned its focus to anti-cis tau antibodies that work to clear phosphorylated tau plaques in AD, CTE, and severe TBI animal models (93, 94, 106) and have reported improved outcomes in vivo. This evidence concerns the gene MAPT and Alzheimer disease.